Trial
NCT05289986
The Effect on Lipid Profile of Switching to Delstrigo in HIV Positive Patients
Phase IVTERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Chelsea and Westminster NHS Foundation Trust
Collaborators
Merck Sharp & Dohme LLC
Condition
Hiv
Intervention
DELSTRIGO 100Mg-300Mg-300Mg Tablet
Why stopped
The CI, sponsor and funder jointly made the decision to end the trial due to lack of recruitment, as well as due to delays it was felt value of the primary endpoint had lessened to a point where its scientific value was questioned.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2026-05-28